Amylyx Pharmaceuticals, Inc. Accounts Receivable
Amylyx Pharmaceuticals, Inc. (AMLX) had Accounts Receivable of $88.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-03-03
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $88.00K.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $132.00K.
- 2025-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $103.00K.
- 2025-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $300.00K.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2025-12-31 | $88.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | $132.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $103.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $300.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $447.00K 10-K · filed 2026-03-03 |
| 2024-09-30 | $1.73M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $4.09M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $20.35M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $40.05M 10-K · filed 2025-03-04 |
| 2023-09-30 | $29.35M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $33.47M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $17.55M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $15.31M 10-K · filed 2024-02-22 |
| 2022-09-30 | $137.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |